Navigation Links
PCAS: 2008 Results
Date:2/18/2009

al invoicing at the beginning of 2007 of a product (phase 2) manufactured in 2006 and representing 4.2 million euros. It is also due to difficulties met by the Group's main customer in the supply of a raw material; difficulties that are being gradually resolved but which impacted sales in 2008 by 1.8 million euros. Lastly, the drop in value of the US Dollar, representing 1.5 million euros, also played a negative role.

As for the Fine Speciality Chemical division, it recorded a fall in sales of 11.6% (8.8 million euros), reflecting the conscious decision to stop manufacture of loss-making products or those considered to be insufficiently profitable at 1.1 million euro, as well as the impact of the unfavourable exchange rate (US Dollar), estimated at -0.9 million euros.

Operational profitability resisted well and debt reduction programme continued in a difficult climate, measures concerning cost reduction and margin improvements were continued to allow the Group to limit the decline in its operational profitability in 2008. The current EBITDA was recorded at 19.3 million euros as compared to 26.8 million euros in 2007. The Group's net debt was reduced to 62.4 million euros as compared to 70.1 million euros in 2007.

In 2008, other operating income and expenses mainly included the profit released by the Finnish subsidiary due to the sale of non-strategic financial assets. In 2007, it included the effects of the posting of the free share programme in particular, implemented in January 2007 (2.0 million euros), as well as restructuring costs (1.0 million euros).

Having taken into account the financial result and taxes, representing â¿¿ 5.4 million euros and -0.7 million euros in 2008 respectively, the PCAS Group's net income recorded a 0.9 million euro loss in 2008 as compared to a 2.7 million euro profit in 2007.

Forecast

Although the crisis in the world's financial
'/>"/>

SOURCE PCAS
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Inverness Medical Innovations Announces Fourth Quarter 2008 Results
2. China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results
3. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
4. Escalon(R) Reports Second Quarter Fiscal 2009 Results
5. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
7. eResearchTechnology, Inc. to Announce Fourth Quarter and Full Year 2008 Results on February 26, 2009
8. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
9. Martek to Announce First Quarter 2009 Results
10. The Quantum Group Reports Year End Results for Fiscal Year 2008
11. Natural Alternatives International, Inc. Announces Fiscal 2009 Q2 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... anything but. Faced with health problems, financial issues and ... 65 years and older suffer from depression. While research ... problem, another group - centenarians - has been left largely ... hasn,t been studied thoroughly in this group," said Adam Davey, ...
... Shows Network Evening News and Newspapers Devote More Coverage to ... , , Health Was the ... Primary Season , , WASHINGTON, ... period of upheaval and transformation, a study from the Kaiser ...
... of ultrasound waves for deep vein thrombosis (DVT) may help ... alone, according to researchers at Emory University. The study will ... in New York City. , "These clots are a main ... quickly you can eliminate them the better," says Karthikeshwar Kasirajan, ...
... anti-viral drug developed by UT Southwestern Medical Center researchers, ... diseases, including potential bioterrorism agents. , In a ... Medicine , groups of guinea pigs infected with a ... fatal disease when treated with bavituximab alone or in ...
... INDIANAPOLIS, Nov. 23 Research professionals from the,health ... practice in which,to network, participate in continuing education ... within their organizations. , ... with which to partner when it became,apparent there ...
... in Palm Springs, California has recently completed work on a comprehensive ... the facility, but the overall recovery experience as well. , ... ... remodeling project, which took nearly a year and half to complete, ...
Cached Medicine News:Health News:Bittersweet milestones 2Health News:Wide-Ranging Study of National News Reveals Health News Comprises Less Than Four Percent of All Coverage 2Health News:Wide-Ranging Study of National News Reveals Health News Comprises Less Than Four Percent of All Coverage 3Health News:Wide-Ranging Study of National News Reveals Health News Comprises Less Than Four Percent of All Coverage 4Health News:Ultrasound waves aid in rapid treatment of DVT 2Health News:UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs 2Health News:Society of Insurance Research and Fletcher/CSI Create First Forum for Research Professionals in the Health Insurance Industry 2Health News:Society of Insurance Research and Fletcher/CSI Create First Forum for Research Professionals in the Health Insurance Industry 3Health News:California Drug Rehab Facility Completes Comprehensive Remodeling Project 2Health News:California Drug Rehab Facility Completes Comprehensive Remodeling Project 3
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... Diagnostics Market by Allergen Source, Product & by End User ... The global allergy diagnostics market is valued ... at a CAGR of 12.67%, to reach $2,230.72 million by ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "X-Ray Detectors Market by Detector Type, Applications & by FPD ... their offering. , The X-ray detectors market ... technological advancements since its inception, such as a shift from ...
Breaking Medicine Technology:Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 2Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 3
... , , ... KERX ) today announced results of the Open Label ... of elevated serum phosphorous levels, or hyperphosphatemia, in patients with ... in Taiwan, enrolled 29 of the 37 Taiwanese patients that ...
... , , , ... today announced results from a Phase II trial of regorafenib (BAY 73-4506), ... in a 31 percent partial response rate and 50 percent stabilization rate ... in an oral session at the joint 15th Congress of the European ...
Cached Medicine Technology:Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 2Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 3Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 4Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
... Designed to accommodate a variety of applications ... the AMAX DestinyPlus is suitable for any ... environment. With a mixed-mode throughput exceeding 95 ... perform a full range of chromogenics, the ...
The TCM4 is able to detect patient changes and is portable....
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)...
... is the only online source of nationally ... critical care nurses and other healthcare professionals., ... so you can take them at your ... certificate is issued upon course completion. The ...
Medicine Products: